Live Breaking News & Updates on Trastuzumab Deruxtecan Plus Olaparib|Page 1

Stay updated with breaking news from Trastuzumab deruxtecan plus olaparib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr González-González on DDR Pathway Inhibition in HER2-low TNBC Breast Cancer Models

Adrian González-González discusses findings from a preclinical study of trastuzumab deruxtecan in combination with DNA damage response (DDR) pathway inhibitors in xenograft models derived from patients with HER2-low triple-negative breast cancer. ....

Adrian Gonz , Washington University School Of Medicine , Washington University School , Adrian González , Washington University School Of Medicine In St Louis , Trastuzumab Deruxtecan In Combination With Dna Damage Response Pathway Inhibitors , Her2 Low Triple Negative Breast Cancer , Trastuzumab Deruxtecan Plus Olaparib ,